Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 4/20 | 0.40 |
| ▸ | PNMT | P11086 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | AGXT | P21549 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21094294 | 0.89 | CCR9 (0.37) | CCR9KIF11PNMTTAAR1SCN5A | |
| SCHEMBL22414493 | 0.89 | PNMT (0.38) | CCR9KIF11PNMTTAAR1PKM | |
| SCHEMBL19806043 | 0.86 | CCR9 (0.49) | CCR9KIF11PKMP2RX1CYP3A4 | |
| SCHEMBL19635634 | 0.84 | TAAR1 (0.42) | CCR9KIF11PNMTTAAR1SCN5A | |
| SCHEMBL29441583 | 0.82 | HDAC4 (0.47) | CCR9KIF11SCN5ASCN9AP2RX1 | |
| SCHEMBL78619 | 0.82 | HDAC4 (0.47) | CCR9KIF11SCN5ASCN9AP2RX1 | |
| SCHEMBL19806085 | 0.81 | KIF11 (0.35) | KIF11PNMTTAAR1SCN5ASCN9A | |
| SCHEMBL18812974 | 0.80 | HTR2A (0.50) | KIF11TAAR1IDO1 | |
| Methyl Alcohol SCHEMBL27512784 | 0.78 | HDAC4 (0.48) | CCR9KIF11SCN5ASCN9AP2RX1 | |
| SCHEMBL21191531 | 0.77 | NR3C1 (0.37) | CCR9KIF11PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466034-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-10-11 | — | — | US | disclosed |
| US-20200385408-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466034-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BRD4, BRD1, BRD2 | CCR9 3312/4885KIF11 1115/4885PNMT 3111/4885 |
| US-20200385408-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BRD4, BRD1, BRD2 | CCR9 3312/4885KIF11 1115/4885PNMT 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.